However, its impact varies: long-term infusion reduces ascites recurrence but not mortality; in large-volume paracentesis (LVP), it lowers PPCD and hyponatremia without affecting mortality or renal impairment; for overt hepatic encephalopathy (HE), albumin improves severity but not mortality; in SBP, albumin reduces mortality and renal impairment risk, a benefit not seen in non-SBP infections; type-1 HRS patients may experience increased survival with each 100 g cumulative albumin dose, but without HRS reversal. This evidence concerns the gene ALB and Hyponatremia.